Alterations of polycomb group (PcG) genes directly modulate the trimethylation of histone H3 lysine 27 (H3K27me3) and may thus affect the epigenome of hepatocellular carcinoma (HCC), which is crucial for controlling the HCC cell phenotype. However, the extent of downstream regulation by PcGs in HCC is not well defined. Using cDNA microarray analysis, we found that the target gene network of 
Introduction
Polycomb group (PcG) proteins are highly conserved epigenetic gene silencers that play important roles in the maintenance of cell fates, developmental programs, and tumorigenesis (1) . PcG proteins bind to specific regions of gene promoters and direct posttranslational modifications at certain histone sites, thereby silencing gene expression (2) (3) (4) (5) . In mammals, PcG is made up of at least two multi-protein complexes:
PRC1 (Polycomb Repressive Complex 1) and PRC2. These complexes work together to carry out their repressive effect (1) . PRC2 is the core of PcG in humans, which consists of the proteins enhancer of zeste homolog 2 (EZH2), suppressor of zeste 12 (SUZ12), and embryonic ectoderm development (EED) (1) . PRC1, the maintenance complex, includes B-lymphoma moloney murine leukemia virus insertion region-1 (BMI1), chromobox homolog 8 (CBX8), and others(1-3). The EZH2 SET (suppressor of variegation, enhancer of zeste, and trithorax) domain specifically catalyzes the trimethylation of Histone 3 lysine 27 (H3K27me3). Methylated H3K27 is recognized by other specific binding proteins, such as PRC1 component, which leads to the compression of chromatin structure and the repression of gene transcription (1) (2) (3) . In addition, some PRC1 complexes can regulate gene expression by monoubiquitylation at Lys 119 of histone H2A (H2AK119ub) via the ubiquitin ligases RING1A (Ring finger protein) and RING1B(3).
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third most common cause of cancer mortality worldwide (6) . EZH2 is a useful biomarker of the aggressive stages of HCC, and its overexpression is associated with the malignant progression of HCC (7) . The same study reported a high level of global H3K27me3 in HCC, which is closely correlated with the vascular invasion of HCC (8) . LncRNA-HEIH is an oncogenic long-noncoding RNA that promotes HCC progression by upregulating the expression of EZH2 in humans (9) . Several microRNAs, such as the putative tumor suppressor microRNA-124, repress the expression of EZH2. Dysregulation of these microRNAs could contribute to EZH2 overexpression in cancer (10) . Inversely, EZH2 exerts its oncogenic function by way of epigenetic silencing of well-characterized tumor suppressor miRNAs, such as miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b (11) . These findings provide significant insights into the molecular mechanisms of PcG involvement in hepatocellular carcinogenesis.
Tumor protein p53 (TP53), a typical tumor suppressor, is a major genetic player in the development of various cancers, including HCC (12) . The aberrant expression of EZH2 has been associated with P53 alteration and contributed to progression and pool prognosis in human squamous cell carcinoma of the esophagus (13) . Activation of TP53 suppresses EZH2 expression through the repression of the EZH2 gene promoter (14) . Inversely, the reduction of EZH2 expression by RNA interference increases the expression of TP53 (15) . These features point to an interesting negative feedback loop between oncogenic EZH2 and tumor suppressor TP53. Despite the importance of EZH2 in controlling the aggressive nature of HCC, the regulation profile of tumor suppressors by PcG in HCC is not well defined.
In this study, we demonstrate potential tumor-promoting actions of PcG in HCC by the H3K27me3-dependent and H3K27me3-independent regulation of downstream gene expression. 
Materials and Methods

Cell culture
The human hepatocellular carcinoma cell line HepG2 (wild-type P53) and Hep3B (P53 null) were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). PLC/PRF5 (human hepatocellular carcinoma with P53 mutant), SMMC-7721 (human hepatocellular carcinoma with wild-type P53), and HO-8910 (human ovarian cancer cell) were obtained from the China Center for Type Culture Collection (Wuhan, China). Wilm's (human nephroblastoma), MCF-7 (human mammary gland adenocarcinoma) and A549 (human lung adenocarcinoma) were obtained from the Cell Culture Center of the School of Basic Medicine, Peking Union Medical College (Beijing, China). The cell cultures were performed as previously described (16) (17) (18) (19) . Briefly, the cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco), RPMI 1640 medium (Gibco) or F12 (Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone) and 1% penicillin-streptomycin.
Chromatin Immunoprecipitation (ChIP) assays
ChIP assays were performed as previously described (16) . In brief, 1×10 6 HepG2 cells were treated with 1% formaldehyde for 10 min at 37 ℃, followed by pulsed ultrasonication to shear cellular DNA. ChIP assays were then carried out with the indicated antibodies according to the protocol of the ChIP Assay kit (Millipore,USA).
After overnight incubation with the antibodies, protein A-or protein G-agarose beads were added. The cross-links between nuclear proteins and genomic DNA were reversed, and DNA pulled down by the antibody was purified by phenol/chloroform extraction. The primer pair (PP) sequences and antibodies for the ChIP assays are 
Western Blotting and Immunofluorescence (IF)
Western blotting and IF staining were performed as previously described (16) .
Antibodies are listed in the supplemental table 1.
Real-time quantitative reverse transcription PCR (qRT-PCR)
qRT-PCR was performed as previously described(16) using an ABI Step One detection system with the primers listed in supplemental table 2. qRT-PCR reactions were performed using SYBR Green (Roche Applied Science, Germany) technology and were repeated at least three times.
Cell proliferation assays
Cell growth and viability were evaluated by using either Bromodeoxyuridine absorbance was measured by using an ELISA plate reader (Bio-Tek Instruments, USA), respectively. For both assays, the mean absorbance values of at least three independent experiments were used for statistical analysis.
Colony forming assays
The colony forming assays were performed as previously described (16) . In brief, 1000 cells were seeded in 6-well plates for 10 days. Colonies were stained with 0.05% crystal violet, photographed, and counted in triplicate using microscope (Nikon Corporation, Japan).
Cell migration assay
Migration assays were performed, as previously described (19) , in 24-well transwell plates (Millipore, USA) using uncoated polycarbonate membranes with 8 mm pores. magnifications. Each condition was assayed in triplicate wells, and the resulting data were subjected to statistical analysis using the Student's t-test.
TUNEL assay
Terminal deoxynucleotidyl transferased UTP nick end labeling (TUNEL) assay (Roche Applied Science, Germany) was used to detect apoptotic cells. Apoptotic cells were determined by counting positive-stained cells in five randomly selected fields in each tumor. At least three tumors in each mouse were randomly selected.
Statistical analysis
All the statistical analyses were performed using SPSS software version 13. control and EZH2 shRNA HepG2 cells cultured in a serum-free medium had a relatively low level of CCNB1 expression. Following the addition of serum into the medium, the protein expression of phospho-CCNB1 dramatically increased at 4-24 hours after serum stimulation in control HepG2 cells (Fig. 1B, Lanes 3-7) . However, in shEZH2 HepG2 cells, the protein expression levels started to increase at 6 hours and returned to a level less than baseline after 12 hours (Fig. 1B, Lane 11 and 12 ).
These data indicate that EZH2 promotes HepG2 cell proliferation at least partly by accelerating G2/M progress. Consistent with this hypothesis, the siRNA-mediated KD of either EZH2 or SUZ12 dramatically suppressed the proliferation of HepG2 cells at the indicated time point, as determined by BrdU or MTT incorporation, respectively (Supplemental Fig. S1C, Fig. 1C and D) . Because cancer metastasis usually involves enhanced cell migration, we sought to determine whether one of the functions of EZH2 is involved in controlling hepatic cancer cell migration. To this end, we performed a modified transwell chamber assay to evaluate the impact of altered EZH2 expression on HCC cell migration. The results indicate that EZH2 siRNA KD significantly reduced the extent of migration (Fig. 2E, p<0 .001) and the colony-forming ability of HepG2 cells (Fig. 2F, p<0 .001).
We next set out to explore whether PcGs promote the growth of HepG2 cell-derived tumors in nude mice. The size of the solid tumor was measured after various periods following transplantation. The shRNA-mediated KD of EZH2, SUZ12, CBX8, or BMI1 significantly suppressed tumor growth and weight in subcutaneous xenografts ( Fig. 2A and B ). In addition, the incidence of apoptotic tumor cells, as assessed by the TUNEL assay, was significantly increased in EZH2, SUZ12, and CBX8 shRNA HepG2 xenografts, with no obvious effect observed for BMI1 shRNA (Fig. 2C and D) . Collectively, these results strongly argue that both 
Identification of downstream pathway of PcG in HCC
Although recent evidence suggests that the abnormal expression of EZH2 and a high level of global H3K27me3 can be attributed to the aggressive nature of HCC (7, 8) 
critical effectors in HCC has not been well defined. It has been reported that the expression of EZH2 is negatively correlated with the p53 pathway in human cancers, suggesting that EZH2 regulates p53 activity or expression (15) . We thus turned our attention to the impact that PcG has on the regulation of TP53 expression.
To rule out the effect of the TP53 mutation on its own expression, we first performed a mutation screen of the entire TP53 locus in HepG2 cells. We focused our analysis on novel changes that were predicted to affect the protein-coding sequence.
We discovered only one variation, P72R, which has been described in a previous report. P72R affects exon 4 of the TP53 gene in HepG2 and is considered a neutral single nucleotide polymorphisms (SNP) (20) . Thus, we investigated the regulatory relationship between PcG and TP53 using HepG2 cells. The reduction of EZH2 levels by shRNA increased the expression of TP53 and its downstream effector P21 levels in HepG2 cells, as determined by qRT-PCR and western blotting (Fig. 4A) . Similarly, the KD of EZH2 by three distinct siRNA clearly increased TP53 and P21 mRNA expression (Fig. 4B) . Next, the shRNA-mediated KD of CBX8 increased the mRNA expression of TP53 and P21 in HepG2 cells (Fig. 4C) . The CBX8-shRNA3 failed to reduce CBX8 expression and was unable to increase the level of TP53 or P21 mRNA (Fig. 4C) . In time-course detection, the mRNA expression of TP53 was elevated by the substantial KD of EZH2 or CBX8 siRNA at days 2 and 4 in both HepG2 and SMMC-7721 cells (Supplemental Fig. S2A and B) . Furthermore, the KD of SUZ12 also increased the protein levels of TP53 and P21 in HepG2 cells (Fig. 4D) . EZH2 siRNA KD moderately increased the mRNA level of TP53 in another type of human cancer cell line, lung adenocarcinoma A549 (Fig. 4E) . However, we didn't observed an obvious effect of EZH2 on repressing TP53 mRNA level in other type tumor cell lines, HO-8910, MCF-7, and Wilm's (Supplemental Fig. S2C ). This result suggests that EZH2 regulates TP53 expression in a tissue-specific manner. Furthermore, inversely correlated with the reduction of PcGs, the mRNA levels of TP53 and CDKN2A were increased in PcG KD HepG2 xenografts (Fig. 4F) . Interestingly, we further found that EZH2 didn't regulate the TP53 mRNA expression in Hep3B with p53-null background and PLC/PRF/5 with p53-mutant background (Supplemental Fig.   S2D ). This result suggests that EZH2 represses TP53 expression depending on wild-type TP53 genomic status.
To gain insight into the role of the PcG in regulating TP53 expression, we performed qRT-PCR analysis on total RNA extracted from HCC liver samples and their matched non-neoplastic counterparts. First, the whole-exome sequencing of TP53 in the primary HCC tissues of 48 patients excluded the typical TP53 mutation, and we further analyzed the mRNA expression of EZH2, SUZ12, CBX8, BMI1, and TP53. These HCCs included cases with wild-type TP53 (19 cases), TP53 with synonymous mutations (three cases), TP53 with the neutral SNP variation (P72R, 21 cases), and TP53 with four previously unreported SNP variations (a total of five cases) (data not shown). Using a large cohort of HCC specimens (n=48), we confirm here that the expression of EZH2, CBX8, BMI1, and SUZ12 was significantly overexpressed in HCC samples compared to their non-tumoral counterparts (Fig. 5 ).
In addition, we found that the TP53 mRNA expression levels are decreased in HCC specimens compared to adjacent tissues (Fig. 5) . Spearman analysis performed using qRT-PCR expression data indicate that the mRNA expression of TP53 was negatively correlated with the upregulation of EZH2, CBX8, and BMI1, but not SUZ12 (Fig. 5 ).
This observation further suggests a potential role for PcGs in the regulation of TP53 in HCC.
We were interested in whether PcG regulated TP53 transcription through an Fig. S3B ). Unexpectedly, we did not find any obvious H3K27me3 modification or an EZH2 binding signal at the promoter loci using H3K27me3 and EZH2 antibody ChIP assays, respectively (Supplemental Fig. S3C and D), suggesting that EZH2 regulates TP53 expression through an H3K27me3-independent mechanism.
PcG directly controls target gene transcription through H3K27me3
In our previous ChIP-on-chip assay (GSE52300), we screened out the H3K27me3-related target gene network of PcG, which contains well-established genes, such as CDKN2A, and other previously unstudied genes in liver cancer cells, including E2F1 and NOTCH2 (21) . The functional importance of these genes in controlling liver function has been established (22, 23) . This finding suggests a preferential epigenetic action of EZH2 on the regulation of the transcription of E2F1 and NOTCH2 in HCC. To test this hypothesis, we performed ChIP assays using three distinct pairs of ChIP primers at E2F1 promoter loci (Fig. 6A) . Using an EZH2-specific antibody, we demonstrated that EZH2 was present at the E2F1 promoter in HepG2 cells (Fig. 6B) . As expected, the KD of EZH2 by shRNA decreased the binding of EZH2 to the E2F1 loci (Fig. 6B) . EZH2-shRNA also led to a significant decrease in the H3K27me3 level at the promoter of the E2F1 locus (Fig.   6C ). In addition, we demonstrated that EZH2 and H3K27me3 were present at the promoter of NOTCH2 and that the KD of EZH2 by shRNA led to a severe decrease in the binding of EZH2 and the H3K27me3 levels at the promoters in HCC (Fig. 6D-6F ). In agreement with a previous report (27) , we identified genes that are targeted by 
defined. In the present study, we found that the expression of TP53 was dramatically repressed by both PRC1 and PC2, and a significant negative correlation between the expression of PcGs and TP53 was found in primary HCC specimens. However, we failed to observe an obvious impact of H3K27me3 on TP53 expression, suggesting that PcG regulates TP53 expression in an H3K27me3 independent manner in HCC.
This activity is presumably dependent on the direct regulation of CDKN2A or E2F1, which are known upstream regulators of the TP53 pathway (28, 29) . The ARF product functions as a stabilizer of the p53 protein, which was responsible for the degradation of p53 (28) . CDKN2A product interacts with and inhibits the oncogenic action of MDM2 by blocking MDM2 induced degradation of p53 and enhancing p53 dependent transactivation and apoptosis (28) . Confusingly, we found that both protein and mRNA levels of Alteration of PcG components was observed in various cancers such as melanoma, lymphoma, and breast and prostate cancer, leading to the hypothesis that PcG has tumor-promoting functions (32) . The overexpression of EZH2 promotes the growth and cell invasion of immortalized human mammary epithelial cells (33) , and the reduction of EZH2 expression inhibits prostate cancer cell proliferation in vitro (34) .
Further studies demonstrate that the oncogenic effect of EZH2 is linked to the H3K27me3 dependent repression of the tumor suppressor genes, including E-cadherin, RUNX3, INK4/ARF (also known as CDKN2A) (24, 35, 36) , and others. Here, we found that the alterations of PcG proteins directly modulate H3K27me3 and may thus affect the HCC epigenome, which is crucial for HCC cell growth both in vitro and in vivo. We also observed that the reduction of EZH2 expression induces G2/M cell cycle arrest in HCC cells. This finding is consistent with a previous report that CDKN2A induces G2 arrest in a p53 independent manner by preventing the activation 
